Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4414/smw.2021.20481 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Latvian Healthcare Professionals' Self-Reported Knowledge, Attitudes, and Behaviors Related to Pregnancy Prevention Program Materials for Valproate-Containing Medicines.
Pharmacy (Basel)
December 2024
Department of Applied Pharmacy, Faculty of Pharmacy, LV-1007 Riga, Latvia and Institute of Public Health, Riga Stradiņš University, LV-1010 Riga, Latvia.
Background: Valproates are recognized for their significant teratogenic risks, which can lead to physical defects and developmental disorders when used during pregnancy. To mitigate these risks, the Pregnancy Prevention Program (PPP) was developed by European regulators for patients and healthcare professionals (HCPs). Despite the crucial nature of this program, the implementation of the PPP does not appear to be fully effective.
View Article and Find Full Text PDFNeuroprotective effects of Apigenin on prenatal Valproic acid-induced autism spectrum disorder in rats.
IBRO Neurosci Rep
December 2024
Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Unlabelled: Valproic acid (VPA) demonstrates teratogenic effects during pregnancy. Prenatal exposure to VPA may result in autism spectrum disorder (ASD) -like phenotypes. Apigenin, a natural flavonoid, has been shown to have neuroprotective impacts due to its antioxidant properties.
View Article and Find Full Text PDFTrends in use of antiseizure medication and treatment pattern during the first trimester in the German Embryotox cohort.
Sci Rep
December 2024
Embryotox Center of Clinical Teratology and Drug Safety in Pregnancy, Institute of Clinical Pharmacology and Toxicology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Because of their developmental toxicity, some antiseizure medication (ASM) should be avoided during pregnancy. This may lead to discontinuation or switching of ASM after recognition of pregnancy, but some of these changes may be suboptimal. Trends in ASM use at conception were analyzed in 3,763 pregnancies prospectively ascertained by a teratology information service in Germany between 2000 and 2018.
View Article and Find Full Text PDFMigraine in the multiple sclerosis prodrome: a prospective nationwide cohort study in pregnant women.
J Headache Pain
December 2024
Norwegian Centre for Headache Research, Norwegian University of Science and Technology, Trondheim, Norway.
Background: People with multiple sclerosis (MS) have an increased risk of migraine. However, little is known about migraine and other headaches during the prodromal phase (before MS symptom onset). Our objective was to study the risk of migraine in women with MS before MS onset.
View Article and Find Full Text PDFThe incorporation of MALDI mass spectrometry imaging in studies to identify markers of toxicity following opioid exposures in mouse fetuses.
Front Toxicol
December 2024
National Center for Toxicological Research (FDA), Division of Systems Biology, Jefferson, AR, United States.
Introduction: In 2015, the FDA released a Drug Safety Communication regarding a possible link between opioid exposure during early pregnancy and an increased risk of fetal neural tube defects (NTDs). At the time, the indications for opioid use during pregnancy were not changed due to incomplete maternal toxicity data and limitations in human and animal studies. To assess these knowledge gaps, largescale animal studies are ongoing; however, state-of-the-art technologies have emerged as promising tools to assess otherwise non-standard endpoints.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!